Ligand Pharmaceuticals stock
LGNDNASDAQLigand Pharmaceuticals Incorporated, HealthcareISIN US53220K5048
60Score 60 out of 100, Neutral
Price and trend
83 / 100
Price history
+54% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since July 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 2.0% below its 52-week high. Largest decline in 20 years: 90% (January 2007 to November 2008).
Chart figures for advanced users
- SMA 50$301.33
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$257.80
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$181.65
- The lowest closing price of the last twelve months.
- Resistance$322.75
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ligand Pharmaceuticals Incorporated belongs to the Biotechnology industry (United States) and, with a market value of $6.33B, is number 63 of 289 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $291.96M (up 8.9%) and adjusted earnings per share of $9.58 (up 19.2%).
- MEQIRI Score 60 out of 100 (Neutral): rank 269 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $154.99, with the price 104% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 176% of earnings over the last 12 months.Fundamentals 58
- High marginNet margin 20.3% over the last 12 months, Biotechnology median −103.7%.Profitability 50
- Analysts expect strong earnings growthUp 18.8% a year through 2028 (estimates from 7 analysts).Growth 61
Weaknesses
- Above fair valuePrice 104% above the fair value of $154.99.Valuation 12
- DilutionShare count up 19% since 2020.Capital allocation 51
- High debtDebt 1.2 times equity (latest quarter), Biotechnology median 0.09.Stability 67
Its standout strengths are momentum and technical analysis, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 61 to 60.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- stable momentum
- price near its 52-week high
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $119.22 and expensive above $221.42 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 10%. At 11% the fair value would be $131.82, at 9% it would be $187.29.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 1% on the twelve months before. Revenue has grown solidly since 2006, at about 3% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 98%, operating 18%, net 46%. Last 12 months: net 20%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 29 Oct 2026EPS reported $2.67 (expected $2.33)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $9.58+3.0%
- Revenue
- $291.96M+0.6%
- Earnings per share
- $11.95−1.3%
- Revenue
- $384.46M−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −3.1%Low end of the adjusted EPS guidance raised to $9.00 (upper end stays at $9.50), with revenue guidance reaffirmed.
“We are increasing the low end of our adjusted diluted earnings per share guidance to $9 per share, while maintaining the upper end at $9.50.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $26.66M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Aryeh JasonSale
10 Nov 2026, Board
- Shares
- 3,000
- Price
- $320.05
- Value
- $960,141
- Aryeh JasonSale
4 Nov 2026, Board
- Shares
- 282
- Price
- $319.99
- Value
- $90,237
- Reardon AndrewSale
2 Nov 2026, CLO & Secretary
- Shares
- 5,000
- Price
- $313.22
- Value
- $1.57M
Show 15 more
- Aryeh JasonSale
2 Nov 2026, Board
- Shares
- 700
- Price
- $320.43
- Value
- $224,298
- Aryeh JasonSale
30 Oct 2026, Board
- Shares
- 1,411
- Price
- $320.24
- Value
- $451,860
- Reardon AndrewSale
2 Oct 2026, CLO & Secretary
- Shares
- 5,000
- Price
- $304.07
- Value
- $1.52M
- Zimmermann MartineSale
10 Sept 2026, Board
- Shares
- 1,200
- Price
- $285.00
- Value
- $342,000
- Reardon AndrewSale
3 Sept 2026, CLO & Secretary
- Shares
- 5,000
- Price
- $286.09
- Value
- $1.43M
- Espinoza OctavioSale
12 Aug 2026, Chief Financial Officer
- Shares
- 31,641
- Price
- $292.07
- Value
- $9.24M
- Haas JasonSale
12 Aug 2026, Board
- Shares
- 7,138
- Price
- $292.81
- Value
- $2.09M
- Reardon AndrewSale
3 Aug 2026, CLO & Secretary
- Shares
- 5,000
- Price
- $288.99
- Value
- $1.44M
- Reardon AndrewSale
1 Jul 2026, CLO & Secretary
- Shares
- 5,000
- Price
- $313.28
- Value
- $1.57M
- Sabba Stephen LSale
16 Jun 2026, Board
- Shares
- 2,145
- Price
- $254.00
- Value
- $544,830
- Haas JasonSale
12 Jun 2026, Board
- Shares
- 6,461
- Price
- $255.58
- Value
- $1.65M
- Aryeh JasonSale
11 Jun 2026, Board
- Shares
- 4,500
- Price
- $250.00
- Value
- $1.13M
- Aryeh JasonSale
10 Jun 2026, Board
- Shares
- 500
- Price
- $250.00
- Value
- $125,000
- Lamattina John LSale
10 Jun 2026, Board
- Shares
- 4,591
- Price
- $250.88
- Value
- $1.15M
- Reardon AndrewSale
1 Jun 2026, CLO & Secretary
- Shares
- 5,000
- Price
- $227.06
- Value
- $1.14M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Ligand Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 60
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Arrowhead PharmaceuticalsARWR $6.66B30
- ImmunityBioIBRX $6.46B37
- BioconBIOCON.NS $6.42B41
- Samsung Epis Holdings0126Z0.KS $6.4B41
- CG OncologyCGON $6.27B41
- Hangzhou Tigermed Consulting300347.SZ $6.12B46
- Mirum PharmaceuticalsMIRM $6.09B38
- Scholar Rock HoldingSRRK $5.71B35
ETFs that hold Ligand Pharmaceuticals
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.73% | 0.49% | €26.29M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.59% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.39% | 0.35% | €1.25B |
Show 5 more
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.36% | 0.30% | €2.31B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.23% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.21% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.21% | 0.30% | €4.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.07% | 0.43% | €2.5B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.